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Abstract
Approximately 75% of breast cancers are estrogen receptor alpha (ERα)-positive and are treatable with endocrine therapies,
but often patients develop lethal resistant disease. Frequent mutations (10–40%) in the ligand-binding domain (LBD) codons
in the gene encoding ERα (ESR1) have been identiﬁed, resulting in ligand-independent, constitutively active receptors. In
addition, ESR1 chromosomal translocations can occur, resulting in fusion proteins that lack the LBD and are entirely
unresponsive to all endocrine treatments. Thus, identifying coactivators that bind to these mutant ERα proteins may offer
new therapeutic targets for endocrine-resistant cancer. To deﬁne coactivator candidate targets, a proteomics approach was
performed proﬁling proteins recruited to the two most common ERα LBD mutants, Y537S and D538G, and an ESR1-YAP1
fusion protein. These mutants displayed enhanced coactivator interactions as compared to unliganded wild-type ERα.
Inhibition of these coactivators decreased the ability of ESR1 mutants to activate transcription and promote breast cancer
growth in vitro and in vivo. Thus, we have identiﬁed speciﬁc coactivators that may be useful as targets for endocrine-
resistant breast cancers.
Introduction
Approximately 75% of breast cancers express estrogen
receptor alpha (ERα) and new therapies are needed for the
~50% of ER-positive tumors that acquire endocrine resis-
tance [1]. Current endocrine therapies include selective ERα
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modulators [2], aromatase inhibitors (AIs) [3], and selective
ERα downregulators (SERDs) [4]. ERα plays a major role
in the development of therapy-resistant tumors, and its
activity is mediated by binding of 17-β estradiol (E2) to its
ligand-binding domain (LBD) for the recruitment of steroid
receptor coactivators (SRCs) and other coactivators for
transcriptional activation of estrogen response element
(ERE)-containing genes [5].
One mechanism for endocrine resistance is thought to be
through acquired mutations in ESR1 (gene encoding ERα).
The ﬁrst ESR1 mutation (Y537N) was identiﬁed in a
metastatic breast cancer patient and conferred ligand-
independent transcriptional activity [6]. Since then, addi-
tional LBD point mutations have been identiﬁed that are
expressed in a subset (10–40%) of metastatic tumors [7–
14]. ESR1 mutations appear to be acquired in response to AI
treatment during metastatic progression [15] and are asso-
ciated with poor survival [15–17]. The Y537S and D538G
mutant receptors possess constitutive ERE-driven tran-
scriptional activity [7–11]. These mutations lock helix 12 of
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the ERα LBD into an agonist-type conformation [7, 9, 18]
and have higher afﬁnities for the SRC-3 coactivator com-
pared to unliganded wild-type (WT) ERα [14, 19].
ESR1 chromosomal translocation events also occur in
endocrine-resistant, metastatic breast cancer patients
resulting in fusion proteins possessing the N terminus and
DNA-binding domain (DBD) of ERα, but containing part-
ners from various genes that replace the LBD [11, 20]. One
such fusion, ESR1-YAP1, induced expression of ERE-
containing target genes in a ligand-independent manner, and
cannot be targeted with standard endocrine therapies since it
lacks a LBD [11].
Understanding how ERα mutant proteins function is
essential for the development of new therapeutics to treat
endocrine-resistant tumors. To deﬁne co-regulators binding
mutant ERα proteins as potential new targets, we proﬁled
their recruitment to Y537S ERα, D538G ERα, and ESR1-
YAP1 proteins bound to EREs using mass spectrometry
(MS). We show that inhibition of the most-enhanced
binding coactivators reduced ERE-driven transcription and
ESR1 mutant expressing breast cancer cell growth.
RESULTS
Identiﬁcation of co-regulators recruited to ERα
mutants
Since Y537S, D538G, and ESR1-YAP1 ERα (Fig. 1a)
promote E2-independent transcriptional activation of an
ERE-dependent reporter (Fig. 1b), we tested whether this
activation is through recruiting or repelling distinct co-
regulators (coactivators and co-repressors). Using our
4xERE DNA pulldown assay to identify co-regulators
recruited to ERα [21], we ﬁrst utilized recombinant WT and
Y537S ERα, along with HeLa S3 nuclear extract (HNE) to
form complexes. Washed complexes were then subjected to
label-free, quantitative MS and bound proteins were nor-
malized by the amount of ESR1 N-terminal peptides bound
(Fig. 1c, top; Supplementary Table 2).
Compared with unliganded WT ERα, a subset of coac-
tivators were recruited in an enhanced manner to Y537S
ERα (Fig. 1c, bottom). Namely, the histone H3 lysine 4
(H3K4) methyltransferase KMT2D complex displayed the
greatest enrichment with Y537S ERα, along with SRC-1,
-2, and -3, p300, CBP, and KMT2D’s paralog, KMT2C.
Immunoblotting validated the enhanced KMT2D and SRC-
3 recruitment (Fig. 1d).
As SRC-3 directly binds Y537S ERα [14, 19], we tested
whether a KMT2D complex [22] would directly interact
with Y537S ERα. Indeed, the binding of the KMT2D
complex was enhanced with Y537S, along with E2-bound
WT, compared to unliganded WT ERα (Fig. 1e). We found
other potential coactivators with enhanced binding to
Y537S ERα (Supplementary Figure 1a). We further vali-
dated PELP1 recruitment by immunoblotting, as an inhi-
bitor disrupting this interaction is described [23]
(Supplementary Figure 1b). We found very few co-
repressors had reduced recruitment to Y537S ERα (Sup-
plementary Figure 1c).
As puriﬁed D538G ERα failed to recruit SRC-3 despite
binding EREs (data not shown), we resorted to using
extracts from transfected 293T cells as sources of WT,
Y537S, and D538G ERα proteins. We again observed
enhanced recruitment of KMT2D and SRCs to Y537S
compared to unliganded WT ERα (Supplementary Figure
2). The D538G mutant also recruited these coactivators, but
three to four times less than that of Y537S. Additional
potential co-regulators displayed enhanced binding to both
ERα mutants. However, for subsequent functional char-
acterization, we chose to focus on SRCs and the KMT2D
complex.
Fig. 1 Proteomics of co-regulators recruited to the Y537S ERα LBD
point mutant. a Schematic diagram of WT, Y537S, and D538G ERα
point mutants (mutations indicated by arrows), and the ESR1-YAP1
fusion protein. Numbers refer to amino-acid residues in ERα and
YAP1. AF1 activation function 1, DBD DNA-binding domain. Hinge,
region between DBD and ligand-binding domain (LBD); AF2 Acti-
vation function 2, WW WW domain, TAD transcription activation
domain. In ESR1-YAP1, blue represents ERα residues (1–365); yel-
low indicates YAP1 residues (230–504). b Mutant ERα proteins dis-
play E2-independent transcriptional activity. Vectors expressing YFP
or YFP-tagged WT, Y537S, D538G, or ESR1-YAP1 proteins were co-
expressed with an ERE-dependent luciferase reporter (pERE-E1b-luc)
in HeLa cells grown in charcoal-stripped fetal bovine serum (FBS).
Cells were then treated with/without 10 nM E2 for overnight. Luci-
ferase activity (RLU relative light units) was assayed from whole-cell
extracts of the cells transfected in triplicate. Data are represented as
mean ± SEM (n= 3); ***p < 0.001. c MS data depicted as a heatmap
for WT or Y537S ERα-dependent coactivators recruited to EREs.
(Top) Schematic of ERE DNA pulldown assay using HeLa S3 NE as
the source of co-regulators (modiﬁed from ref. [21]) and puriﬁed ERα
proteins. (Bottom) MS data were analyzed from duplicate reactions
using a label-free method and depicted as in ref. [21]. Peptides number
of peptides detected; amount (vsESR1) amount normalized by sum of
area under the curve for six N-terminal ESR1 peptides (see Supple-
mentary Table 2). Fold change represents the ratio of amount detected
normalized to unliganded WT ERα. Fold change cutoff used was ≥1.5.
SRC-1 to -3 (gene symbols: NCOA1, NCOA2, NCOA3), p300 (gene
symbol: EP300), CBP (gene symbol: CREBBP). d Immunoblotting
validation of KMT2D and SRC-3 enrichment with puriﬁed Y537S
ERα bound to EREs using independent DNA pulldown samples in the
absence of E2. ERα protein binding was assayed by an N-terminal (N-
term) antibody. TBP serves as a loading control. 2% input represents
2% of the starting HNE employed in the ERE DNA pulldown. e
Y537S ERα and the KMT2D complex interact directly in an enhanced
manner relative to unliganded WT ERα. ERE DNA pulldown assays
were performed with puriﬁed ERα proteins and a puriﬁed KMT2D
“fusion” complex [22], and then analyzed by immunoblotting. (i)
Representative immunoblot probing for select KMT2D complex
members and ERα. (ii) Quantiﬁcation of KMT2D signal across three
independent pulldown assays. Binding was quantiﬁed using Image J
and normalized to ERα signal
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SRCs are critical for ERα LBD mutant activity and cell
growth
We next tested the functional consequence of enhanced
SRC-ERα mutant interactions on transcription. Knockdown
of SRC-3 using published siRNAs [24] signiﬁcantly
reduced both Y537S and D538G ERα-mediated transcrip-
tional activity on the ERE-Luc reporter (Fig. 2a). Treatment
with a small molecule inhibitor (SMI), SI-1, which inhibits
the activities of all three SRCs (IC50= 0.2 μM) [25] and
reduces SRC protein levels (Fig. 2b), severely reduced the
transcriptional activities of WT and mutant ERα (Fig. 2c).
Cell viability was minimally affected (Supplementary Fig-
ure 3a). We also tested whether the combination of an oral
SERD and SI-1 would further reduce LBD mutant ERα
transcriptional activity. We focused on AZD9496 [26]
(AZD) as it: (1) reduced endogenous ERα protein, (2)
was signiﬁcantly more potent than ICI182,780 (ICI, ful-
vestrant) in reducing mutant ERα transcriptional activities
(unlike another SERD GDC-0810 [27] (GDC; Supple-
mentary Figure 3b-d), and (3) AZD was reported as more
effective than ICI at inhibiting tumor growth promoted by
Y537S ERα [14]. The combination of SI-1 and AZD
synergistically reduced both Y537S and D538G activities
on the ERE-luciferase (Luc) reporter (Fig. 2d, e, Supple-
mentary Table 4).
We tested whether SRC inhibition would affect growth
of stably expressing WT or Y537S ERα MCF-7 cell lines
[28]. SI-1 at 400 nM reduced viability in both WT and
Y537S ERα-expressing cells by 91% (Fig. 2f). When
combinations of SI-1 with AZD or ICI were tested, a
synergistic reduction in viability of Y537S ERα-expressing
cells was found at the two highest combined doses or
highest combined dose, respectively (Fig. 2f and Supple-
mentary Figure 3e; Supplementary Tables 5 and 6). Thus,
SI-1 combined with AZD was most effective in reducing
both transcription and cell growth mediated by mutant ERα
proteins.
Inhibiting SRCs and mutant ERα most effectively
reduces patient-derived xenograft tumor growth
We next tested the efﬁcacy of an improved pan-SRC
inhibitor (SI-2) [25], AZD, or the combination in a
patient-derived xenograft (PDX) expressing Y537S
ERα (WHIM 20 [11]) for tumor reduction (Fig. 3a). SI-2
was chosen instead of SI-1, given its reduced IC50 (3.4 nM)
and ability to reduce ER- tumor growth [25]. After
tumors grew to 350 mm3, mice were randomized, E2
was withdrawn to mimic AI treatment, and mice were
then treated with control vehicle, SI-2, AZD, or the com-
bination. After 4.5 weeks, SI-2 alone signiﬁcantly reduced
tumor volume, AZD gave a larger reduction, but the com-
bination gave the most signiﬁcant reduction in tumor
growth.
We next conﬁrmed that the drugs indeed affected
their intended targets and tested for effects on apoptosis
and proliferation. First, as expected, AZD treatment
signiﬁcantly reduced ERα expression in tumor lysates.
Unexpectedly, AZD treatment upregulated SRC expression
(Fig. 3b, Supplementary Figure 4a), which may have
relevance for patients receiving AZD monotherapy in
clinical trials (NCT02248090/NCT03236974). Second,
we tested the expression of a classical ER target gene,
PR (Fig. 3c, Supplementary Figure 4a). While SI-2
did not affect PR expression, AZD clearly did. Third,
we found that SI-2 increased an apoptosis marker
(cleaved PARP protein), while AZD decreased
proliferation as measured by BrdU incorporation (Fig. 3d, e,
Supplementary Figure 4b). Finally, we did not observe
any signiﬁcant toxicity with any drug treatment after
examining recipient mouse livers by histochemistry
and measuring body weights (Supplementary Figures 4c-d).
Thus, our PDX data support a potential new treatment
regime for breast cancers bearing ESR1 LBD
mutations, which is to combine a SRC inhibitor with an oral
SERD.
Fig. 2 SRCs are key co-regulators of WT, Y537S, and D538G ERα
transcriptional activity and are essential for breast cancer cell growth. a
Knockdown of SRC-3 by co-transfection of HeLa cells with an siRNA
targeting pool reduced transcriptional activity of LBD point mutant
ERα proteins, as assayed by an ERE-luciferase reporter, in hormone-
depleted media. Data are represented as mean ± SEM (n= 3); ***p <
0.001. RLU relative light units. b A “pan-SRC” inhibitor, SI-1,
reduced all three SRC protein levels in MCF-7 breast cancer cells
treated overnight, as assayed by immunoblotting. β-actin serves as a
loading control. c SRC inhibitor SI-1 reduced WT, Y537S, and
D538G ERα transcriptional activity at concentrations higher than the
established IC50. Vectors expressing YFP-tagged WT, Y537S, and
D538G ERα proteins were co-expressed with pERE-E1b-luc in HeLa
cells, and then cells were treated with dimethyl sulphoxide (DMSO,
vehicle control) or SI-1 overnight. Luciferase activity was measured as
in Fig. 1b. Data are represented as mean ± SEM (n= 3). d,e Combi-
nation of an SRC inhibitor (SI-1) and an oral SERD (AZD9496)
synergistically reduce Y537S (d) and D538G (e) mutant ERα tran-
scriptional activity. Experiment was done as in (c), except that
AZD9496 was added with or without SI-1 to co-transfected HeLa
cells. Data are represented as mean (n= 3). f The oral SERD
AZD9496 is more effective than the SRC inhibitor SI-1 in reducing
cell viability of MCF-7 lines expressing WT or Y537S ERα. The
lentiviral transduced MCF-7 stably expressing cell lines were treated
with vehicle (DMSO) or different concentrations of AZD9496 or SI-1
as indicated. After 6 days of treatment, viability was assayed by a
MTT assay. Data are represented as mean ± SEM (n= 3). Synergism
was observed with combination (Combo) treatments 4 and 5 (12.5/
200 nM AZD9496/SI-1; 25/400 nM AZD9496/SI-1) in Y537S ERα-
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Fig. 3 Inhibition of SRCs and ERα reduces tumor burden in a PDX
model of Y537S ERα breast cancer. Signiﬁcance was determined
using one-way ANOVA and Tukey’s test to correct for multiple
comparisons. *p < 0.05; **p < 0.01; ***p < 0.001. a Tumor volume (n
= 8) is reduced with treatment of either SI-2 or AZD9496, and further
reduced upon treatment with a combination of both inhibitors. Data are
represented as mean ± SEM. b–e Quantiﬁcation of tumor immuno-
blotting (n= 6/treatment) performed with Image J analysis relative to
GAPDH expression or imaging data (n= 8) unless otherwise indi-
cated. Data are represented as mean ± SD. ud undetected. Color legend
is the same as in (a). b Quantiﬁcation of ERα, SRC-1, and SRC-3
protein expression across tumors. By Dixon’s Q test, the tumor sam-
ples in the last lane probed for SRC-1 and SRC-3 (Supplementary
Figure 4a) were outliers at 99% conﬁdence and thus excluded from the
Image J analysis. c The ERα target gene PR displays reduced
expression with AZD9496 and combination treatment. d BrdU is
decreased in the AZD9496 and combination therapy groups (n= 8
mice per group, with mean ± SD of three slides for each mouse
counted). e Cleaved PARP is increased with SI-1 treatment and
decreased with AZD9496 and combination therapies
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KMT2C/2D are novel coactivators for Y537S ERα
From above, we found that the KMT2C/2D complexes were
preferentially enriched with Y537S ERα (Fig. 1c, Supple-
mentary Figure 2a). To determine the functional role of
KMT2C/2D, we tested whether their depletion would affect
Y537S ERα-mediated reporter expression. Knocking down
KMT2C, KMT2D, or both together reduced Y537S ERα
transcriptional activity (Fig. 4a). Upon double KMT2C/2D
knockdown, WT ERα transcriptional activity was also
reduced (Fig. 4b). However, ESR1-YAP1 transcriptional
Fig. 4 Knockdown of KMT2C/2D reduces WT and Y537S ERα
transcriptional activity and breast cancer cell growth. a HeLa cells
grown in phenol red-free, charcoal-stripped media were co-transfected
with pERE-E1b-luc, YFP-tagged Y537S ERα, and different siRNAs
(25 nM each for 50 nM total). Cell lysates were assayed for luciferase
activity (RLU). Data are represented as mean ± SEM (n= 3); ***p <
0.001. NC#1 siRNA served as the negative control for KMT2D tar-
geting siRNA, while Control-A siRNA pool served as the negative
control for KMT2C targeting siRNA pool. b Transfection of siRNAs
targeting KMT2C and KMT2D reduced expression of the pERE-E1b-
luc reporter, as compared to non-targeting siRNAs (siControl), in
HeLa cells co-transfected with YFP-tagged WT or Y537S ERα
vectors, but not an YFP-tagged ESR1-YAP1 fusion. Luciferase
activity was measured as in Fig. 1b. Data are represented as mean ±
SEM (n= 3); **p < 0.01; ***p < 0.001. c Knockdown of KMT2C and
KMT2D in lentiviral transduced stably expressing WT or Y537S
MCF-7 cells results in reduced anchorage-independent growth in soft
agar and confers sensitivity to anti-estrogens. siRNAs (same as above)
were transfected into the two cell lines at a ﬁnal concentration of
100 nM (50 nM each), and then re-plated in 24 well plates 24 h later.
After 1 week with either vehicle or anti-estrogen (100 or 1000 nM 4-
hydroxytamoxifen (Tam) or ICI) treatment, colonies formed in soft
agar were counted and quantiﬁed. Data are represented as mean ± SEM
(n= 4); *p < 0.05; **p < 0.01; ***p < 0.001
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activity was not affected, ruling out a general transcriptional
effect.
We additionally found that KMT2C/2D knockdown
reduced anchorage-independent growth of WT, Y537S, and
D538G ERα-expressing cells (Supplementary Figure 5),
with signiﬁcant differences observed between WT and
mutant ERα data. More importantly, knockdown of
KMT2C/2D signiﬁcantly sensitized the partially resistant
Y537S ERα cells to anti-estrogens currently given in the
clinic (Fig. 4c). Overall, our data reveal an important
functional role for KMT2C/2D with Y537S ERα in tran-
scription and cell growth.
SRCs and KMT2D are crucial for growth of inducible
LBD mutant ERα cells
As our above cell lines stably overexpressed LBD ERα
mutants [28], we created MCF-7 cell lines supporting
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conditional (doxycycline (Dox)-inducible) expression of
FLAG-tagged WT, Y537S, or D538G ERα. The FLAG tag
did not impair the transcriptional activities of ERα proteins
(Supplementary Figure 6). Dox addition to cells grown in
charcoal-stripped media induced expression of these ERα
proteins, with Y537S and D538G ERα accumulating to a
similar extent but less than WT (Fig. 5a). We next per-
formed co-immunoprecipitations to test whether SRC-3 and
KMT2D displayed enhanced association with inducible
mutant ERα proteins under hormone-depleted conditions.
We found greatest KMT2D and SRC-3 association with the
Y537S mutant, with less recruited to D538G ERα (Fig. 5b).
Importantly, the Dox-inducible mutant ERα proteins acti-
vated endogenous ERα target genes (GREB1 and TFF1) in
a hormone-independent manner and D538G ERα had a
weaker effect than Y537S, in accordance with other models
[7, 9, 29–31] (Fig. 5c and Supplementary Figure 7a). We
next asked whether ablation of these key co-regulators
would inhibit the viability of these cells. Consistently, SI-1
signiﬁcantly reduced the viability of all ERα-expressing
cells (Fig. 5d), while knockdown of KMT2C/2D selectively
affected WT and Y537S ERα-expressing cells (Fig. 5e).
Knockdown of KMT2C/2D modulates Y537S ERα
direct target gene expression
We next tested the effect of KMT2C/2D depletion on
GREB1 and TFF1 gene expression in our Dox-inducible
MCF-7 cells. KMT2C/2D knockdown reduced Y537S
ERα-mediated transcription of both genes (Fig. 5f and
Supplementary Figure 7b). In WT ERα cells, the loss of
KMT2C/2D also reduced TFF1 mRNA, but GREB1 or
ESR1 were unaffected. We extended our analysis to 10 total
ERα target genes by depleting only KMT2D using a vali-
dated siRNA [32], as KMT2D had greater recruitment than
KMT2C to Y537S ERα (Fig. 1c). We observed that Y537S
mutant expression regulates select ERα targets, a subset of
which is reduced by KMT2D depletion (Supplementary
Figure 7c).
Chromatin immunoprecipitation (ChIP) was used to
examine whether the ERα mutants bound EREs [33–35]
located upstream of the GREB1 and TFF1 gene transcrip-
tion start sites (TSS) in a Dox-dependent manner (Fig. 5g
and Supplementary Figure 7d). All ERα proteins displayed
Dox-dependent enrichment on EREs upstream of the
GREB1 and TFF1 TSS, but not on a negative control region
[36]. Thus, the binding of the LBD mutant ERα proteins to
multiple EREs suggests direct regulatory roles in regulation
of these genes.
Chromatin occupancy of Y537S ERα and KMT2D are
positively correlated
As SRC-3 and p300 are co-localized with Y537S ERα on
chromatin [29], we next tested whether KMT2D chromatin
occupancy correlated with Y537S ERα. We performed
ChIP using a validated KMT2D antibody [37, 38] (Fig. 5h
and Supplementary Figure 7e). KMT2D occupancy
increased in Y537S ERα cells in a Dox-dependent manner
for all EREs assayed, but not for the control region, without
increased KMT2D protein expression (Supplementary Fig-
ure 7f). Thus, Dox-induced occupancy of EREs by Y537S
Fig. 5 SRCs and KMT2C/2D promote cell growth and transcription of
ERE-containing target genes in conditionally expressed (Dox-induci-
ble) WT and mutant ERα MCF-7 cell lines. Prior to all assays, cell
lines were grown in charcoal-stripped, phenol red-free media with/
without Dox for at least 2 days. a Conﬁrmation of FLAG-tagged WT,
Y537S, and D538G ERα Dox-inducible expression in MCF-7 cells
transduced with speciﬁc lentiviruses. Immunoblotting was performed
on whole-cell extracts with FLAG, ERα (HC-20 antibody), or β-actin
(loading control) antibodies. *, Nonspeciﬁc band. →, Position of
endogenous ERα. b KMT2D and SRC-3 co-immunoprecipitate with
mutant ERα. Whole-cell extracts from Dox-inducible MCF-7 cells
were subject to immunoprecipitation of FLAG, followed by immu-
noblotting. For analysis, intensities were normalized for different
precipitated ERα levels by Image J. c Dox-inducible expression of
Y537S and D538G ERα in MCF-7 cells results in activation of two
canonical ERα target genes independent of E2. Cell lines were treated
with Dox and the WT ERα line was treated (±) 10 nM E2 overnight,
followed by RNA isolation. Relative levels of GREB1 or TFF1
mRNAs were determined by RT-qPCR with ESR1 mRNA as the
normalizer. Data are represented as mean ± SEM (n= 3); **p < 0.01;
***p < 0.001. d, e Cell viability (measured by Cell Titer Glo as RLU)
of Dox-inducible WT, Y537S, and D538G ERα expressing MCF-7
lines (induced as above). *p < 0.05; **p < 0.01; ***p < 0.001. d Cell
viability is reduced in all three cell lines upon treatment with SRC
inhibitor SI-1 (1 μM) after 3 days' exposure. DMSO served as the
vehicle control. Data are represented as mean ± SEM (n= 3). e Cell
viability of Dox-inducible WT and Y537S ERα-expressing MCF-7
lines, but not the D538G-expressing ERα line, is reduced upon
knockdown of KMT2C and KMT2D after 3 days exposure to 100 nM
total siRNA (50 nM each). Data are represented as mean ± SEM (n=
3). f Knockdown of KMT2C and KMT2D reduces Y537S ERα-
enhanced expression of GREB1 and TFF1. Cells were transfected with
siRNAs (100 nM total, 50 nM each). Relative levels of GREB1 or
TFF1 mRNAs were determined by RT-qPCR using ACTB mRNA as
the normalizer. Data are represented as mean ± SEM (n= 3); *p <
0.05; **p < 0.01; ***, p < 0.001. g Dox-induced FLAG-tagged WT,
Y537S, and D538G ERα proteins occupy EREs of GREB1 and TFF1
genes in MCF-7 cells, implying direct transcriptional regulation. In
contrast, ERα proteins minimally occupy a negative control region
from intron 4 of the CCND1 gene, which lacks endogenous ERα
binding [36]. Where indicated, WT ERα cells were treated with
100 nM E2 for 45 min. ChIP assays employed an antibody against
FLAG to IP the FLAG-tagged ERα proteins and associated DNA.
Isolated DNA was assayed by ChIP-qPCR. Representative data were
plotted relative to percentage of starting input chromatin and are
represented as mean of triplicate qPCR reactions ± SEM. Supple-
mentary Figure 7d shows a repeated ChIP assay. h KMT2D occupies
EREs of GREB1 and TFF1 genes in a Dox-dependent manner corre-
lating with increased Y537S ERα occupancy. ChIP-qPCR was per-
formed using an antibody to KMT2D. Representative data were
plotted as above and the CCND1 gene intron 4 served as a negative
control region. Supplementary Figure 7e shows a repeated ChIP assay
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Fig. 6 The ESR1-YAP1 fusion protein recruits the 26S proteasome for
activated transcription of an ERE-driven luciferase reporter. a MS data
depicted as a heatmap (displayed as in Fig. 1c) for ESR1-YAP1-
dependent coactivators recruited to EREs from HNE. Recombinant
puriﬁed WT or ESR1-YAP1 proteins were added to duplicate ERE
DNA pulldown reactions. Fold change cutoff was ≥1.5 for enrichment
over unliganded WT ERα. *ESR1 normalized ESR1 (see Supple-
mentary Table 2). **YAP1 YAP1 corrected for ESR1. b Immuno-
blotting validation of the 26S proteasome being recruited to ESR1-
YAP1. Independent ERE DNA pulldown samples were used to detect
proteins recruited to ESR1-YAP1 compared to WT with/without E2 (i)
or compared to WT or Y537S ERα (ii). Levels of ERα bound to the
EREs were determined with an ERα antibody recognizing an N-
terminal (N-term) epitope. TBP served as a loading control. 3% HNE,
3% of the starting HeLa S3 NE employed in the ERE DNA pulldown.
c A 26S proteasome inhibitor, MG132, reduces ESR1-YAP1 tran-
scriptional activity on an ERE-driven luciferase reporter. HeLa cells
grown in phenol red-free, charcoal-stripped media were co-transfected
with a vector expressing YFP-tagged ESR1-YAP1 protein and pERE-
E1b-luc. Cells were then treated with vehicle (0.1% DMSO) or 1 μM
MG132 for overnight. Luciferase activity (RLU relative light units)
was assayed from whole-cell lysates. Data are represented as mean ±
SEM (n= 3); ***p < 0.001
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Fig. 7 Proteasome inhibition reduces viability of breast cancer cells
expressing the ESR1-YAP1 fusion and modulates ESR1-YAP1 target
gene expression. T47D cell lines expressing these constructs were
grown in phenol red-free, charcoal-stripped media for at least 2 days. a
Increasing concentrations of bortezomib reduce cell viability of HA
epitope-tagged YFP, WT ERα, and ESR1-YAP1 stably expressing
T47D cell lines. (i) Cell viability was measured (via Cell Titer Glo as
RLU) after 3 days of bortezomib or vehicle (DMSO) treatments. Data
are represented as mean ± SEM (n= 3). (ii) Expression levels of ERα
proteins were assayed in whole-cell extracts made from HA-tagged
YFP, WT ERα, and ESR1-YAP1 expressing T47D cell lines. The N-
terminal ERα antibody was used to detect endogenous ERα (denoted
by →) as well as the ESR1-YAP1 fusion. β-actin served as a loading
control. b Expression of HA-tagged ESR1-YAP1 activates expression
of two classical ERE-containing target genes as compared to E2-
deprived HA-tagged WT ERα. WT ERα-expressing cells were treated
with/without 10 nM E2 for 24 h. Relative levels of TFF1 or PGR
mRNAs were determined by RT-qPCR using ACTB mRNA as the
normalizer. Data are represented as mean ± SEM (n= 3); **p < 0.01;
***p < 0.001. c ESR1-YAP1 directly occupies certain EREs of the
TFF1 and PGR genes. Where indicated, HA-tagged WT ERα cells
were treated with 100 nM E2 for 45 min before ChIP assays. ChIP-
qPCR assays employed an antibody against HA to IP the HA-tagged
ERα proteins and associated DNA. Representative data were plotted
relative to percentage of starting input chromatin, which was repre-
sented as the mean of triplicate qPCR reactions ± SEM. CCND1 gene
intron 4 served as a negative control region. Supplementary Figure 8d
shows a repeated ChIP assay. d Proteasome inhibitor treatment of
T47D cells expressing HA-tagged ESR1-YAP1 modulates ERE-
containing target gene expression. Cells were treated with vehicle
(0.1% DMSO) or 4 or 16 nM bortezomib for 17 h. Relative levels of
PGR, TFF1, ESR1, or ESR1-YAP1 mRNAs were determined by RT-
qPCR using GAPDH mRNA as the normalizer. Data are represented as
mean ± SEM (n= 3); *p < 0.05; ***p < 0.001
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ERα is correlated with increased recruitment of KMT2D
and enhanced transcription of GREB1 and TFF1.
Co-regulators recruited to the ESR1-YAP1 fusion
We next investigated co-regulator recruitment to ESR1-
YAP1, which contains the N terminus and DBD, but lacks
the LBD, of ERα fused in-frame to the C terminus of the
Yes-associated protein 111 (Fig. 1a). ESR1-YAP1 promotes
high levels of expression of an ERE-dependent reporter
without E2 (Fig. 1b and Supplementary Figure 6a). We
compared co-regulator recruitment to either puriﬁed WT
ERα or ESR1-YAP1 bound to ERE DNA in the absence of
E2 (Fig. 6a). After normalization for ERα-binding differ-
ences, the ESR1-YAP1 protein did not recruit more SRC-3
and KMT2D as compared to WT ERα, unlike the LBD ERα
mutants (validated in Fig. 1d). Instead, the ESR1-YAP1
protein recruited many subunits of the 26S proteasome (Fig.
6a). Immunoblotting validated enhanced proteasome
recruitment (SUG1/PSMC5 and 20S C2/PSMA1) of ESR1-
YAP1 vs. WT ERα, even with E2 (Fig. 6b). We further
validated that the 26S proteasome was recruited to ESR1-
YAP1 in E2-deprived T47D stable cell line [11] extracts
(Supplementary Figure 8a).
The 26S proteasome plays a role in WT ERα degradation
that is linked with the receptor’s ability to activate ERE-
driven reporter genes [39–41]. We thus tested whether a
proteasome inhibitor, MG132, would similarly inhibit
ESR1-YAP1 transcriptional activity. Indeed, MG132 treat-
ment of cells transfected with an ERE-driven reporter and
an ESR1-YAP1 expression plasmid reduced Luc activity, as
compared to the vehicle control (Fig. 6c). Interestingly,
MG132 or the FDA-approved proteasome inhibitor, borte-
zomib, could inhibit the transcriptional activity of a GAL4
DBD-YAP1 fusion (Supplementary Figure 8b).
Proteasome activity is important for ESR1-YAP1-
mediated cell growth and gene expression
We next tested the functional signiﬁcance of the ESR1-
YAP1: 26S proteasome interaction in T47D stable lines
expressing HA-tagged YFP, WT ERα, or ESR1-YAP1
proteins (Fig. 7aii and Supplementary Figure 8c). Increasing
concentrations of bortezomib treatment for 3 days efﬁ-
ciently reduced the growth of all three T47D lines compared
to the vehicle control (Fig. 7a,i).
We next wanted to deﬁne the effect of ESR1-YAP1
expression in T47D cells grown in an E2-deprived state on
ERα target gene expression. The ESR1-YAP1 fusion pro-
moted the expression of two target genes, TFF1 and PGR,
signiﬁcantly above the level of unliganded WT ERα-
expressing cells (Fig. 7b), even though much less ESR1-
YAP1 fusion was expressed (Fig. 7a, ii and Supplementary
Figure 8c). The regulation of these two genes is likely
direct, as ChIP assays revealed ESR1-YAP1 occupancy at
two deﬁned ERE enhancer-like sequences [35, 42] (Fig. 7c
and Supplementary Figure 8d).
The effect of proteasome inhibition on TFF1 and PGR
gene expression in E2-deprived ESR1-YAP1-expressing
cells was tested by treating cells with bortezomib (Fig. 7d).
Proteasome inhibition had both a dose-dependent and gene-
speciﬁc effect on the ESR1-YAP1 targets, decreasing PGR
and increasing TFF1, which resembles the effect of pro-
teasome inhibitors on these genes after E2 treatment of
MCF-7 cells [43–46]. Bortezomib decreased endogenous
ESR1 mRNA expression, consistent with prior reports [43,
47]. Finally, we observed that bortezomib stimulated ESR1-
YAP1 mRNA expression (driven by the CMV promoter),
which may explain why bortezomib did not severely reduce
ESR1-YAP1 cell viability as compared to overexpressed
WT ERα (Fig. 7a). Thus, the proteasome modulates ESR1-
YAP1 target genes and cell growth, suggesting a new
approach for treating tumors bearing this class of resistance
mutation.
Potential clinical relevance of mutant ERα-binding
coactivators
To investigate whether the expression levels of the coacti-
vators identiﬁed in this study correlate with patient out-
comes, we queried two existing expression data sets—the
Symmans Breast 2 ER-positive tamoxifen-treated patients
[48] or ER-positive breast cancer patients treated with
endocrine therapy (in KM plotter [49]; Supplementary
Figure 9). In the Symmans data set, we found signiﬁcantly
higher KMT2D mRNA levels in patients who had a meta-
static occurrence after 3 years of tamoxifen treatment vs.
those that had not (panel a). We also found that higher SRC-
3 and proteasomal subunit mRNA levels correlated with
reduced survival from distant metastasis (panels b, c). In the
KM plotter analysis, we found that higher KMT2D, but not
KMT2C, mRNA signiﬁcantly correlated with reduced
recurrence-free survival (panel d). Finally, we assayed a
metastatic breast cancer mutation/ampliﬁcation database
[50] and found that the ESR1 LBD mutations were not
present in patients with mutations in either KMT2C or
KMT2D genes (panel e).
DISCUSSION
Different therapeutic approaches have been proposed to
inhibit LBD mutant ERα proteins in breast cancers (Fig. 8)
[23, 26, 27, 29–31, 51–54]. However, resistance to these
therapies will occur. We envisioned that by deﬁning the co-
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regulator “complexome” of each ESR1 mutant protein we
could identify new potential therapeutic targets (Fig. 8c).
We identiﬁed coactivators that exhibit enhanced binding
to ERα mutant proteins. Consistent with prior literature [7,
9, 14, 18, 19, 55, 56], SRCs display enhanced recruitment to
EREs bound by the two LBD ERα mutants as compared
with unliganded WT ERα. Since all three SRCs are
recruited to the two LBD ERα mutants, therapeutic inter-
vention likely must be directed toward all three proteins.
Accordingly, we show that a pan-SRC SMI can effectively
inhibit LBD ERα mutant activity and breast cancer cell
growth (Fig. 2). Furthermore, combining pan-SRC SMI and
oral SERD treatments have a synergistic effect on both
LBD mutant transcriptional activity and cell growth (Fig.
2), and, more importantly, Y537S ERα-expressing PDX
tumor growth (Fig. 3).
Our results further reveal coactivator complexes pre-
ferentially interacting with ERα mutants. First, we show
that KMT2C/2D H3K4 methyltransferases are preferentially
recruited to Y537S (Fig. 1c, Supplementary Figure 2a).
These complexes were previously shown to coactivate E2-
bound WT ERα in MCF-7 cells [57–60]. Although Y537S
and D538G are one amino-acid residue apart in helix 12, it
is striking that the KMT2C/2D complex is preferentially
recruited to Y537S, and that it promotes the growth of
Y537S ERα-expressing cells (Fig. 5e, Supplementary Fig-
ure 5). Detailed structural analysis is needed to examine
how such coactivator-binding selectivity is achieved. As
expression of Y537S ERα confers poor prognosis in
metastatic breast cancer [16], our data suggest that devel-
oping targeted inhibitors of KMT2C/2D would be worth-
while for inhibition of Y537S ERα mutant activity.
Furthermore, KMT2D is oncogenic in ER-positive breast
cancers resistant to PI3Kα inhibitors [61].
Second, we have proﬁled coactivators bound to ESR1-
YAP1, as it represents a “paradigmatic” gene fusion that
activates ERE-driven transcription (Figs. 1b, 7b, Supple-
mentary Figure 6). The ESR1-YAP1 fusion biochemically
behaved in a distinct manner from the two LBD ERα
mutants, as it displayed enhanced recruitment of the 26S
proteasome (Fig. 6, Supplementary Figure 8a). Further-
more, proteasome activity is important for both ESR1-
Fig. 8 Potential ways to inhibit
mutant ERα-driven breast cancer
cell growth. In metastatic breast
cancer, the ESR1 gene encoding
ERα is mutated in exon 6 (by
translocations creating in-frame
fusion proteins such as ESR1-
YAP1) or in exon 8 (by point
mutation in the LBD creating
Y537S or D538G ERα mutants).
While other laboratories have
published pharmacological
inhibitor strategies for reducing
ESR1 mutant gene transcription
(a), for inhibiting the LBD
mutant ERα proteins directly
(b), and for inhibiting
downstream gene products
whose expression is driven by
LBD mutant ERα proteins (d),
we propose that inhibition of
key mutant ERα coactivators,
such as KMT2C/2D, SRC
coactivators, and the
proteasome, is a new therapeutic
approach for inhibiting mutant
ERα-driven breast cancer cell
growth (c). See also Discussion
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YAP1 transcriptional activity and growth of breast cancer
cells (Figs. 6c, 7a, b). As the proteasome inhibitor borte-
zomib is in clinical trial for ERα-positive, metastatic
breast cancer (NCT01142401), we propose that it may
reduce ESR1-YAP1-mediated tumor growth. Recently,
other ESR1 gene fusions [20] have been identiﬁed in ER-
positive metastatic disease and whether they also utilize
the proteasome for their activity should be further
investigated.
In summary, our study utilized an MS approach proﬁling
three different mutant ERα proteins, which identiﬁed
coactivators preferentially recruited to LBD mutants vs. an
ESR1 gene fusion. We further showed that inhibition of
these coactivators decreased ERE-driven transcription
and reduced growth of breast cancer cells expressing
these ERα mutants. Importantly, the combination of a pan-
SRC inhibitor and oral SERD reduced the tumor growth
of a human PDX expressing the Y537S ERα mutant,
suggesting this as a potential new therapeutic strategy.
We further identify additional potential therapeutic
targets for Y537S ERα-expressing breast cancers (KMT2C/
2D complexes) and for the ESR1-YAP1 fusion (26S pro-
teasome) for which no prior targets were known.
Together, our data support the idea that differential coacti-
vator recruitment may be partly responsible for the ability of
ERα mutant proteins to potentially drive metastatic breast
cancer.
Materials and methods
Cell lines
Lines were obtained from BCM tissue culture core (ori-
ginally from ATCC) unless otherwise indicated. STR pro-
ﬁling validated MCF-7 cell line authenticity. All lines tested
negative for mycoplasma. MCF-7 and T47D cell lines sta-
bly expressing WT, Y537S, and D538G ERα were descri-
bed [28]. C-terminal HA-tagged YFP, ESR1-WT, and
ESR1-YAP1 lentiviral T47D cell lines were generated as in
[11] using the pCD516B-2 vector (System Biosciences).
Dox-inducible N-terminal FLAG-tagged WT, Y537S,
and D538G ERα stable MCF-7 cell lines were constructed
with pCW-FLAG-ERα lentiviruses. All lines were main-
tained in media containing 10% fetal bovine serum and
switched to phenol red-free, hormone-depleted media
before treatments.
Plasmids
pCW-FLAG-WT, Y537S, or D538G were created from
pCW-Cas9 [62] (Addgene). pFLAG-CMV constructs were
made from pFLAG-CMV2 (Sigma). YFP-tagged ESR1-
YAP1 was constructed by PCR of the ESR1-YAP1 open
reading frame (ORF) [11], followed by ligation into
digested pECFP-C1 (Clontech). pBIND-YAP1 (GAL4
DBD-YAP1 amino acid 230–504 fusion expression plas-
mid) was constructed by ligation into pBIND (Promega).
All constructs were sequenced.
ERE DNA pulldown assays
The ERE DNA pulldown was described [21]. One micro-
gram of puriﬁed receptor was added to 2–2.5 mg HNE and
15 pmol 4xERE-E4 DNA immobilized on Dynabeads M-
280 streptavidin (Invitrogen). For Supplementary Figure 8a,
NE was made as described [63]. For direct interaction
assays, 10 μl of the puriﬁed recombinant KMT2D “fusion”
complex [22] was incubated with 0.25 μg of puriﬁed ERα
for 1.5 h at 4 °C followed by washes and elution [21].
Mass spectrometry
MS was performed and analyzed as described [21]. All data
sets are summarized in Supplementary Tables 1, 2, and 7.
The raw MS proteomics data were deposited to the Pro-
teomeXchange Consortium (http://proteomecentral.
proteomexchange.org), data set identiﬁer: PXD005887.
Recombinant ERα proteins
Flag-tagged ERα ORFs were expressed using the Baculo-
Direct N-terminal Expression kit (Invitrogen). Infected Sf9
cells were lysed in lysis buffer (50 mM Tris-Cl, pH 7.5,
500 mM NaCl, 15% glycerol, 0.01% NP40, 10 mM β-gly-
cerophosphate and protease inhibitor cocktail (Roche)),
followed by puriﬁcation using anti-FLAG M2 antibody-
conjugated beads and 3 × FLAG peptide (Sigma).
Co-immunoprecipitations
Dox-treated MCF-7 cells expressing WT or LBD mutant
ERα proteins were lysed in NETN buffer [21]. Three mil-
ligrams whole-cell extract was incubated for 4 h at 4 °C
with 5 μg mouse anti-FLAG-pre-bound Protein G Dyna-
beads (Invitrogen) and washed with NETN and PBS.
Reagents
Dimethyl sulphoxide, 17β-estradiol (E2), 4-hydro-
xytamoxifen, ICI182,780 (ICI), MG132, and Dox were
purchased from Sigma. Bortezomib (Selleckchem),
AZD9496 (MedChemExpress), and GDC0180 (Active
Biochem) were from listed vendors. SI-1 and SI-2 have
been described [25]. Antibodies are listed in Supplementary
Table 3.
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Luc reporter assays and siRNA transfections
For ERE-Luc assays, HeLa cells were transfected with
pERE-E1b-Luc [39] and ERα expression vector using
Lipofectamine LTX (Invitrogen), and lysed in Glo Lysis
Buffer (Promega). For GAL4-Luc assays, cells were trans-
fected with pBIND-YAP1 and pG5luc (Promega). Luc
activity was measured on a Berthold luminometer as
described [64]. Cells were co-transfected with pERE-E1b-
luc, ERα expression plasmids, and siRNAs using Trans-IT-
TKO (Mirus Corp.) or RNAimax (Invitrogen). siRNAs are
listed in Supplementary Table 3.
Cell viability and soft agar assays
Cell viability or soft agar anchorage-independent cell
growth was measured after 3 days by either a CellTiter-
Glo® Luminescent assay (Promega) or by a MTT assay
[65].
Chromatin immunoprecipitation
Cells in hormone-depleted media were subject to ChIP
assays performed using the EZ-ChIP kit (Millipore) as
described [21]. See Supplementary Table 3.
Calculations of synergism and IC50
Synergism between two drugs was deﬁned as a combination
index < 1 using CompuSyn (http://www.combosyn.com/) or
Calcusyn (http://www.biosoft.com/w/calcusyn.htm) soft-
ware [66]. IC50 values were determined by using Very
Simple IC50 Tool Kit (http://www.ic50.tk/).
Statistical analysis
P values were calculated using Student’s t-test (two-sample,
two-tailed) to compare two means or ANOVA (ordinary,
one-way) followed by adjusting for multiple comparisons
using the Dunnett or Tukey method. P values < 0.05 were
considered signiﬁcant. For statistics, experiments were
performed with three to eight biological replicates (see
ﬁgure legends).
Real-time reverse transcription
Total RNA was isolated with Direct-zol RNA MiniPrep
(Zymo Research) or RNeasy (Qiagen) kits. cDNA synthesis
and real-time reverse transcription (RT-qPCR) data analysis
were carried out as described [64]. See Supplementary
Table 3 for primers.
PDX experiments
Experiments were carried out in accordance with protocol
AN-1875 approved by the BCM Institutional Animal Care
and Use Committee. WHIM 20 PDX was transplanted as
described [11] into 4–5-week-old female SCID/Beige mice
(Envigo). Mice were palpated semi-weekly, and tumor
growth measured using calipers. When tumors reached
~350 mm3 (volume= L×((W×W)/2)), the mice were rando-
mized into four treatment groups (n= 10 each): (1)
AZD9496 5 days/week by oral gavage once daily, 5 mg/kg
body weight (b.w.) [14, 26]; (2) SI-2 twice daily 5 days/
week by intraperitoneal (i.p.) injection at 2 mg/kg b.w. [25];
(3) combination of both inhibitors as described; and (4)
control PBS vehicle (oral and i.p.). Mice were sacriﬁced and
tissues harvested at 4 months post transplantation. Tumor
volume of eight mice per group (which completed at least
4.5 weeks of treatment) was analyzed. Representative
tumors (n= 6/treatment) were lysed in RIPA buffer with
phosphatase and protease inhibitors (Calbiochem). Hema-
toxylin and eosin staining and immunohistochemistry were
performed by the Lester and Sue Smith Breast Center
Pathology Core at BCM. After staining, images were cap-
tured on an OLYMPUS DP73 microscope. For BrdU ana-
lysis, 7 mg/ml BrdU (Sigma) was prepared in PBS and i.p.
injected at 10 µl/g b.w. After 2 h, the mice were sacriﬁced
(n= 8). Slides were stained by BD Pharmingen in Situ-
Detection KIT II and were visualized with diaminobenzi-
dine tetrahydrochloride (Dako), and counterstained with
Harris hematoxylin. Images were analyzed in Matlab by the
Integrated Microscopy Core at BCM. The investigators
were not blinded to allocation during experiments and
outcome assessment. No statistical methods were used to
predetermine sample size estimate.
Patient data analysis
Oncomine was used to query the Symmans Breast 2 data
set. KM plotter (kmplot.com) was used to query the ER-
positive patients treated with endocrine therapy. See Sup-
plementary Figure 9 for more details.
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